In a patient with typhoid who has been treated with cefixime 200 mg twice daily and ofloxacin 200 mg twice daily for 10 days, with a temperature of 98.8 °F but persistent fever, what is the appropriate next step in management?

Management of Persistent Fever After Typhoid Treatment

Switch to IV ceftriaxone immediately or add azithromycin to the current regimen, as the combination of cefixime and ofloxacin has likely failed due to fluoroquinolone resistance, which affects >70% of typhoid isolates. 1

Understanding the Clinical Situation

Your patient's temperature of 98.8°F (37.1°C) is actually normal, but the patient's subjective complaint of persistent fever requires careful evaluation. This discrepancy suggests either:

• Recent fever resolution with residual symptoms
• Measurement timing issues (fever may be intermittent)
• Treatment failure with fluoroquinolone-resistant organism

Why the Current Regimen May Have Failed

The combination of cefixime 200mg BD + ofloxacin 200mg BD faces significant challenges:

Fluoroquinolone Resistance is Rampant:

• More than 70% of S. typhi isolates (particularly from Asia) are fluoroquinolone-resistant 1
• Nalidixic acid resistance serves as a marker for reduced fluoroquinolone susceptibility—if the organism is nalidixic acid-resistant, ofloxacin will fail even if disc testing shows "susceptibility" 1
• Studies show 89-97% of isolates are resistant to fluoroquinolones 2, 3

Cefixime Has Documented Limitations:

• Treatment failure rates of 4-37.6% when used as monotherapy 1
• Significantly slower fever clearance (median 8.5 days) compared to ofloxacin (4.4 days) in susceptible strains 4
• The 200mg BD dosing may be subtherapeutic (standard is 400mg daily or 200mg BD for adults)

Recommended Next Steps

Immediate Actions:

1. Verify actual fever pattern: Document temperature every 4-6 hours for 24 hours to distinguish true persistent fever from subjective symptoms

2. If fever is truly present (>38°C):

   • Switch to IV ceftriaxone 2-4g daily (first-line for fluoroquinolone-resistant typhoid) 1
   • All isolates reported in UK surveillance (2006) were ceftriaxone-sensitive 1
   • Continue for 14 days total to reduce relapse risk (<8% with ceftriaxone) 1

3. Alternative oral option if patient stable:

   • Azithromycin 500mg-1g daily for 7-14 days 5, 1
   • Superior to fluoroquinolones with lower clinical failure (OR 0.48) and shorter hospital stays 5
   • Relapse rate <3% 1
   • However, emerging resistance noted (8.4% in some studies) 3

Diagnostic Workup:

• Repeat blood cultures (highest yield in first week, but still valuable) 1
• Stool and urine cultures (become positive after first week) 1
• Request antibiotic sensitivity testing with specific attention to:
  • Nalidixic acid sensitivity (marker for fluoroquinolone resistance)
  • Ceftriaxone/cefotaxime sensitivity
  • Azithromycin sensitivity if available

Monitor for Complications:

Since symptoms persist beyond 10 days, assess for:

• Gastrointestinal bleeding or perforation (occurs in 10-15% if illness >2 weeks) 1
• Typhoid encephalopathy
• Hepatic dysfunction (check liver enzymes)
• Bone marrow suppression (complete blood count)

Critical Pitfalls to Avoid

Do not continue the current failing regimen simply because the measured temperature is normal—clinical judgment trumps a single normal reading when the patient reports persistent symptoms.

Do not rely on ciprofloxacin disc testing alone for sensitivity determination—it is unreliable unless the organism is also nalidixic acid-sensitive 1

Do not use short courses—typhoid requires 14 days of treatment to minimize relapse risk 1

Do not assume the combination therapy was adequate—while cefixime-ofloxacin combinations are used in India 6, the evidence shows this is less effective than ceftriaxone or azithromycin monotherapy in resistant strains 5, 7

Evidence Quality Considerations

The WHO 2024 guideline 5 provides the most recent high-quality evidence showing azithromycin superiority over fluoroquinolones. The UK guidelines 1, while from 2009, remain highly relevant as they specifically address fluoroquinolone resistance patterns that have only worsened since publication. Recent research 7, 2, 8 confirms these resistance patterns persist and are expanding globally.

The case report of prolonged fever despite appropriate therapy 8 demonstrates that fever may persist for 11 days even with effective antibiotics (meropenem + azithromycin), so patience is warranted if the correct antibiotic is being used and the patient is clinically stable.